Description: Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta.
Home Page: www.quincetx.com
QNCX Technical Analysis
601 Gateway Blvd
South San Francisco,
CA
94080
United States
Phone:
415 910 5717
Officers
| Name | Title |
|---|---|
| Dr. Leslie J. Holsinger Ph.D. | Consultant |
| Dr. Dirk Thye M.D. | CEO & Director |
| Mr. Ted Monohon | VP of Fin., Principal Financial Officer & Chief Accounting Officer |
| Ms. Stacy Roughan | VP of Corp. Communications & Investor Relations |
| Ms. Mary Ellen Sillivos | VP of HR |
| Mr. Brendan Hannah M.B.A. | Chief Bus. Officer |
| Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D. | Chief Medical Officer |
| Dr. Stewart A. Low Ph.D. | Head of Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.234 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-05-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |